SARS_CoV_2 mutation literature information.


  Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine.
 PMID: 34835288       2021       Vaccines
Abstract: Neutralization activity against the D614G, B.1.1.7, and B.1.351 variants were also analyzed.
Method: Three clinical isolates of SARS-CoV-2 were obtained and propagated in Vero E6 cells as previously described: D614G (hCoV-19/Italy/UniSR1/2020; GISAID Accession ID: EPI_ISL_413489), B.1.1.7 (Alpha) (19/Italy/LOM-UniSR7/2021; GSAID Accession ID: EPI_ISL_1924880), B.1.351 (Beta) (hCoV-19/Italy/LOM-UniSR6/2021, GISAID Accession ID: EPI_ISL_1599180).
Result: The highest AUC was observed for the D614G variant followed by the B.1.1.7 and the B.1.351 (Figure 4).


  Phylogenetic and full-length genome mutation analysis of SARS-CoV-2 in Indonesia prior to COVID-19 vaccination program in 2021.
 PMID: 34840498       2021       Bulletin of the National Research Centre
Abstract: Furthermore, it also found that D614G mutation appeared in 103 Indonesian SARS-CoV-2 isolates.
Result: In this study, D614G mutation was detected in 103 Indonesian SARS-CoV-2 isolates.
Figure: A Distribution of D614G mutation from various provinces in Indonesia; B 3D structure visualization of SARS-CoV-2 S protein.


  Codon usage, phylogeny and binding energy estimation predict the evolution of SARS-CoV-2.
 PMID: 34841034       2021       One health (Amsterdam, Netherlands)
Abstract: Second, the host-specific D614G mutation becomes prevalent starting from March 2020.
Introduction: Another amino acid variation of the spike protein, which appeared in mid-2020 and then became prevalent, is D614G.
Result: Notably, D614G is recorded for SARS-CoV and other human CoVs since 2004.


  A next generation sequencing (NGS) analysis to reveal genomic and proteomic mutation landscapes of SARS-CoV-2 in South Asia.
 PMID: 34841355       2021       Current research in microbial sciences
Discussion: B.1.1.8, B.1.1.25, B.1.1.70, B.1.1.80, B.1.1.306 and B.1.1.316 lineages were found predominant in our analysis, all carrying D614G, RG203KR, Q675H mutations.
Discussion: One investigation has demonstrated that the D614G mutation in the Spike protein is associated with high fatality rates.
Discussion: Presence of D614G mutation in the first sequenced sample from Bangladesh indicates the presence of this mutation since the inception of COVID-19 infection and transmission in Bangladesh and explains the reason for the dominance of G-clade mutation in Bangladesh.


  Phylogenomics and population genomics of SARS-CoV-2 in Mexico during the pre-vaccination stage reveals variants of interest B.1.1.28.4 and B.1.1.222 or B.1.1.519 and the nucleocapsid mutation S194L associated with symptoms.
 PMID: 34846283       2021       Microbial genomics
Introduction: Mutation D614G of the SARS-CoV-2 spike protein was the first mutation implicated in increased transmission and a more efficient viral replication in human cells.
Introduction: Shortly after the appearance of D614G, other mutations in the Receptor Binding Domain (RBD) of the spike protein appeared, including but not limited to K417N, L452R, E484K and
Method: We marked the important mutations S477N, T478K, E484K, D614G, P681H/R and T732A.


  Molecular insights into receptor binding energetics and neutralization of SARS-CoV-2 variants.
 PMID: 34848718       2021       Nature communications
Introduction: In this regard, some mutations in SARS-CoV-2 are responsible for large conformational changes that may enhance infection, such as those located in the distal region of the spike protein and near the fusion region as the well-known D614G.


  Rapid Identification of SARS-CoV-2 Variants of Concern Using a Portable peakPCR Platform.
 PMID: 34852455       2021       Analytical chemistry
Introduction: For example, the D614G variant has been shown to increase the viral load of infected patients and has replaced the original variant since June 2020 around the globe.


  Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2).
 PMID: 34855904       2021       PloS one
Abstract: Furthermore, niclosamide remains its potency against the D614G, Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants.
Method: Briefly, human bronchial epithelial cells were apically infected with the European D614G strain of SARS-CoV-2 (BavPat1 D614G) at a multiplicity of infection (MOI) of 0.1 and cult
Result: Importantly, niclosamide also blocked the replication of the European BavPat D614G, B.1.1.7, B.1.351 and B.1.617.2 variant with an IC50 of 0.06 muM, 0.08 muM, 0.07 muM, and 0.08 muM respectively (Fig 2).


  Differential Interactions between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern.
 PMID: 34856802       2021       Journal of chemical theory and computation
Result: Although our results are accordant with recently published studies, the reason why Kappa/Delta and Epsilon behaviors are distinctive remained to be further studied, and it might stem from the limitation in our model, as we only employed the L452R mutation in RBD for the Epsilon variant without a D614G mutation.


  Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
 PMID: 34858404       2021       Frontiers in immunology
Result: In order to further corroborate whether these antibodies were also able to neutralize viral infection in a cell culture, we performed cVNT for lineage B SARS-CoV2 (D614G) and the Alpha, Gamma, and Delta variants.
Result: The GMT values obtained by cVNT for D614G strain and the Alpha, Gamma, and Delta variants were 74.8 (95% CI 59.8-93.6), 32.1(95% CI 20.1-51.1), 15.8 (95% CI 9.5-26.2) and 7.9 (95% CI 5.2-12), respectively.
Result: The results obtained showed that, as compared to the D614G strain, there was a 2.33-fold decrease in neutralizing antibodies against the Alpha variant, a 4.73-fold reduction against the Gamma variant and a 9.46-fold reduction against the Delta variant ( Figure 2A ).



   Filtrator